Quest Diagnostics' (DGX) first-quarter 2023 results are likely to reflect an impressive performance in its non-COVID-19 base business amid inflationary pressure and labor challenges.
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.
Quest Diagnostics' (DGX) upgrade to advanced diagnostics and support services is likely to feature personalized patient access to service centers and mobile phlebotomists.
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.

5 Upcoming Dividend Increases To Start Q2

11:47am, Thursday, 30'th Mar 2023
All these stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 10.1% and a median increase of 7.6%.
Quest Diagnostics (DGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Investors are optimistic about Quest Diagnostics (DGX) on solid fourth-quarter 2022 performance and its strategies to accelerate growth.
Quest Diagnostics' (DGX) latest panels provide consumers a deeper look into their health, helping to prepare them for meaningful discussions with their healthcare providers
These services by Quest Diagnostics (DGX) are available to recipients and living donors across the United States (excluding Alaska and Hawaii), broadening access for both donor and patient.
Quest Diagnostics (DGX) now offers professional laboratory management services for nine of Northern Light Health's hospital laboratories.
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Quest Diagnostics (DGX) is building strong platforms to focus on high-growth areas like molecular genomics and oncology.
Quest Diagnostics core business is experiencing strong growth and has a structure that could potentially exceed market expectations. The current valuation seems very promising and making an entry at t
Quest Diagnostics' revenue and earnings dropped in 2022. Decent dividend growth should be in the company's future.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE